CN1765882A - Preparation method of water-soluble vitamin D2 - Google Patents
Preparation method of water-soluble vitamin D2 Download PDFInfo
- Publication number
- CN1765882A CN1765882A CN 200410040903 CN200410040903A CN1765882A CN 1765882 A CN1765882 A CN 1765882A CN 200410040903 CN200410040903 CN 200410040903 CN 200410040903 A CN200410040903 A CN 200410040903A CN 1765882 A CN1765882 A CN 1765882A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- water
- soluble
- emulsifier
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 title claims abstract description 147
- 239000011653 vitamin D2 Substances 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002061 ergocalciferol Drugs 0.000 title abstract 4
- 235000001892 vitamin D2 Nutrition 0.000 title abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000839 emulsion Substances 0.000 claims abstract description 35
- -1 glyceryl fatty acid ester Chemical class 0.000 claims abstract description 26
- 238000003756 stirring Methods 0.000 claims abstract description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 22
- 229930195729 fatty acid Natural products 0.000 claims abstract description 22
- 239000000194 fatty acid Substances 0.000 claims abstract description 22
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930006000 Sucrose Natural products 0.000 claims abstract description 7
- 239000005720 sucrose Substances 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000010298 pulverizing process Methods 0.000 claims abstract description 6
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims abstract description 5
- 238000004945 emulsification Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229920002521 macromolecule Polymers 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 8
- 239000008103 glucose Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 2
- 230000001678 irradiating effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- QSVJYFLQYMVBDR-UHFFFAOYSA-N Ergosterin Natural products C1C(O)CCC2(C)C3=CCC4(C)C(C(C)C=CC(C)C(C)C)CCC4C3=CC=C21 QSVJYFLQYMVBDR-UHFFFAOYSA-N 0.000 abstract 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 description 13
- 150000003710 vitamin D derivatives Chemical class 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 9
- 229930003316 Vitamin D Natural products 0.000 description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 9
- 235000019166 vitamin D Nutrition 0.000 description 9
- 229940046008 vitamin d Drugs 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 208000037147 Hypercalcaemia Diseases 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000148 hypercalcaemia Effects 0.000 description 4
- 208000030915 hypercalcemia disease Diseases 0.000 description 4
- 239000012043 crude product Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000003217 Tetany Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001416150 Bos indicus x Bos taurus Species 0.000 description 1
- 206010060774 Chondrosis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010060919 Foetal malformation Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 208000036684 familial hypoparathyroidism Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 231100001229 severe poisoning Toxicity 0.000 description 1
- 230000002037 soft tissue calcification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明涉及维生素D2领域,特别涉及水溶性维生素D2的制备方法领域。The invention relates to the field of vitamin D2 , in particular to the field of preparation methods of water-soluble vitamin D2 .
背景技术Background technique
维生素D2是人和动物维持正常生命活动与健康所必须的微量有机化合物之一,药品、食品和饲料中都可以适量添加维生素D2来满足人或动物有规律地从外界摄取。维生素D2是在植物中发现的维生素D的主要天然形式。(参见中国专利95118188.2)。而维生素根据其溶解度分为两类即脂溶性维生素(A、D、E、K)等,或水溶性维生素(B1、B2、B6、B12,叶酸、烟酸及维生素C)]等。[见《药物化学》第15章,一、维生素的分类(中央电大农医部王淑霞)。由于维生素D2不溶于水而溶于脂肪及脂溶剂,因此在食物中常与脂质共存,在肠道吸收时也与脂质的吸收密切相关,当人或动物对脂质的吸收不良时,脂溶性维生素D2的吸收会减少,从而引起相应的缺乏症。在医学上维生素D2的主要适应症包含三个方面,一、用于维生素D缺乏症的预防与治疗。如:绝对素食者、肠外营养病人,胰腺功能不全伴吸收不良综合症、肝胆疾病(肝功能损害、肝硬化、阻塞性黄疸)、小肠疾病(脂性腹泻、局限性肠炎、长期腹泻),胃切除等。二、用于慢性低钙血症、低磷血症、佝偻病及伴有慢性肾功能不全的骨软化症、家族性低磷血症及甲状旁腺功能低下(术后,特发性或假性甲状旁腺功能低下)的治疗。三、用于治疗急、慢性及潜在手术后手足抽搐症及特发性手足抽搐症。而动物维生素D2的缺乏症的特征表现为:维生素D2不足时,即使钙、磷充足,动物也不能很好的利用,钙、磷、镁在骨骼中的沉积会下降;幼龄动物的成骨作用发生障碍,出现佝偻症和软骨症,牙齿发育不良,生长受阻;成年动物发生骨质疏松症,易骨折,关节变形;母畜孕期维生素D2过度缺乏会造成新生幼仔先天畸形,母畜本身也会受到损害;家禽缺乏维生素D2可降低产蛋量和孵化率,蛋壳薄而易脆裂。因此在现代机械化人工大量饲养动物的条件下更需补充维生素D2。然而过量使用维生素D2是有害的,据有关医学资料提示在短期内摄入大剂量或长期服用超剂量维生素D2,可导致严重中毒反应。维生素D2中毒引起的高钙血症,可引起全身性血管钙化、肾钙质沉淀及其他软组织钙化,而致高血压及肾功能衰竭,上述不良反应多发生于高钙血症和伴有高磷血症时。儿童可致生长停滞、屡见于长期应用维生素D2每日1800单位后,中毒剂量可因个体差异而不同。即使每日应用1万单位超过数月后,对正常成人亦可致毒性反应。维生素D2中毒可因肾、心血管功能衰竭而致死。妊娠动物摄入过量维生素D2可致胎仔畸形,动物维生素D2中毒表现为高尿钙、厌食、恶心呕吐,口渴、多尿、乏力、关节疼痛及一般定向障碍,过量的维生素D2引起血钙过高使多余的钙沉积在心脏、血管、关节、心包或肠壁,导致心力衰竭,关节强直或肠道疾患,甚至死亡。维生素D的两种主要形式是维生素D2和维生素D3,一般认为它们显示出相似的生物活性,有一样的代谢作用(即活化和分解代谢),但是有资料认为;“维生素D3的毒性10~20倍于维生素D2,这是因为维生素D3很容易被代谢为25-羟-D3的原因,Trunnel等(1990)给15头7~10日龄的奶牛犊和杂种牛喂维生素D、A和E复合物,每天维生素D100万单位、维生素E88万单位。结果所有的牛均表现出精神不振、厌食、脱毛,步行困难等症状,其中6头在饲喂13~27日后死亡。对其中3头其行解剖发现,在肺动脉的内表面有红褐色沉淀物,肝脏轻微变色。对8头牛中的6头牛进行血液化学检查,发现血浆中25-羟-D3和钙2+的浓度均有明显升高。”(参见《脂溶性维生素添加剂的安全性》作者黄涛、陈喜斌、盛金朋等人,中国养殖网)。根据中华人民共和国国家标准GB14880-94《食品营养强化剂使用卫生标准》对维生素D(D2或D3)的使用范围和每公斤使用量限定为;乳及乳饮料10~40μg,人造奶油125~156μg,乳制品63~125μg,婴幼儿食品50~100μg(1μg维生素D=40单位维生素D)。而对于维生素D做为安全饲养添加量的国家标准为维生素D(IU/kg),猪114-240,鸡200~500,鸭400~900。由于维生素D的用量以μg为单位,脂溶性维生素D2与食品或饲料混合时,很难控制用量而且不易混合均匀而导致产品不合格,因此,国内食品或饲料行业中添加维生素D2的产品极少。维生素D2在目前全世界的年消耗量约为1800吨,其中70%左右用于饲料添加剂。我国年需求量约为100多吨。现在全球维生素D2市场被巴斯夫公司、罗氏公司、日清化学公司所把持,主要供应欧洲和日本市场,这些维生素制造巨头在全球的维生素销售中,40%以上是通过多维和预混料销售给终端客户的。根据四川省专利信息中心提供的检索查新报告,经过对中外专利数据库的检索结果表明尚未发现有水溶性维生素D2方面的技术资料。Vitamin D 2 is one of the trace organic compounds necessary for humans and animals to maintain normal life activities and health. Medicines, foods and feeds can be supplemented with vitamin D 2 to meet the regular intake of humans or animals from the outside world. Vitamin D2 is the main natural form of vitamin D found in plants. (referring to Chinese patent 95118188.2). Vitamins are divided into two categories according to their solubility, namely fat-soluble vitamins (A, D, E, K), etc., or water-soluble vitamins (B 1 , B 2 , B 6 , B 12 , folic acid, niacin and vitamin C)] wait. [See Chapter 15 of "Medicinal Chemistry", 1. The classification of vitamins (Wang Shuxia, Department of Agriculture and Medicine, Central TV University). Since vitamin D2 is insoluble in water but soluble in fat and fat solvents, it often coexists with lipids in food, and is also closely related to the absorption of lipids when absorbed in the intestinal tract. When humans or animals malabsorb lipids, Absorption of fat-soluble vitamin D2 decreases, causing a corresponding deficiency. In medicine, the main indications of vitamin D 2 include three aspects, 1. It is used for the prevention and treatment of vitamin D deficiency. Such as: absolute vegetarians, parenteral nutrition patients, pancreatic insufficiency with malabsorption syndrome, hepatobiliary diseases (liver function damage, cirrhosis, obstructive jaundice), small intestinal diseases (fatty diarrhea, regional enteritis, long-term diarrhea), gastric Excision etc. 2. For chronic hypocalcemia, hypophosphatemia, rickets and osteomalacia with chronic renal insufficiency, familial hypophosphatemia and hypoparathyroidism (postoperative, idiopathic or pseudo Hypoparathyroidism) treatment. 3. For the treatment of acute, chronic and potential postoperative tetany and idiopathic tetany. The characteristics of vitamin D2 deficiency in animals are as follows: when vitamin D2 is insufficient, even if calcium and phosphorus are sufficient, animals cannot make good use of them, and the deposition of calcium, phosphorus, and magnesium in bones will decrease; Osteogenesis is obstructed, rickets and chondrosis appear, tooth dysplasia, and growth retardation; adult animals suffer from osteoporosis, easy fractures, and joint deformation; excessive vitamin D2 deficiency during pregnancy can cause congenital deformities in newborn pups. It can also suffer itself; vitamin D deficiency in poultry can reduce egg production and hatchability, with thin and brittle eggshells. Therefore, vitamin D 2 supplementation is even more necessary under the conditions of modern mechanized artificial large-scale animal feeding. However, excessive use of vitamin D 2 is harmful. According to relevant medical data, taking large doses of vitamin D 2 in a short period of time or taking excessive doses of vitamin D 2 for a long time can lead to severe poisoning reactions. Hypercalcemia caused by vitamin D2 poisoning can cause systemic vascular calcification, renal calcium precipitation and other soft tissue calcification, resulting in hypertension and renal failure. The above adverse reactions mostly occur in hypercalcemia and hypercalcemia. Phosphate. Children can cause growth stagnation, which is often seen after long-term application of vitamin D 2 1800 units per day, and the toxic dose may vary due to individual differences. Even after daily application of 10,000 units for more than several months, it can cause toxic reactions to normal adults. Vitamin D 2 poisoning can cause death due to renal and cardiovascular failure. Excessive intake of vitamin D 2 in pregnant animals can cause fetal malformation, animal vitamin D 2 poisoning manifests as hypercalciuria, anorexia, nausea and vomiting, thirst, polyuria, fatigue, joint pain and general disorientation, excessive vitamin D 2 causes Hypercalcemia causes excess calcium to deposit in the heart, blood vessels, joints, pericardium, or intestinal wall, leading to heart failure, stiff joints or intestinal disorders, and even death. The two main forms of vitamin D are vitamin D 2 and vitamin D 3 , which are generally believed to exhibit similar biological activities and have the same metabolic effects (ie, activation and catabolism), but some data suggest that; "The toxicity of vitamin D 3 10 to 20 times that of vitamin D 2 , this is because vitamin D 3 is easily metabolized into 25-hydroxy-D 3 , Trunnel et al. (1990) fed 15 7 to 10-day-old dairy calves and hybrid cattle D, A and E complex, 1 million units of vitamin D and 880,000 units of vitamin E per day. As a result, all the cattle showed symptoms such as lack of energy, anorexia, hair loss, and difficulty in walking, and 6 of them died after feeding for 13 to 27 days. Three of them were dissected and found that there were reddish-brown deposits on the inner surface of the pulmonary artery and the liver was slightly discolored. Six of the eight cattle were examined for blood chemistry, and 25-hydroxy-D 3 and calcium 2 in plasma were found The concentration of + all increased significantly." (See Huang Tao, Chen Xibin, Sheng Jinpeng, etc., authors of "The Safety of Fat-Soluble Vitamin Additives", China Aquaculture Network). According to the National Standard of the People's Republic of China GB14880-94 "Hygienic Standards for the Use of Food Nutrition Fortifiers", the scope of use and the amount per kilogram of vitamin D (D 2 or D 3 ) are limited to: 10-40 μg for milk and milk drinks, 125 μg for margarine ~156μg, dairy products 63~125μg, food for infants and young children 50~100μg (1μg vitamin D=40 units of vitamin D). The national standard for vitamin D as a safe feed addition is vitamin D (IU/kg), 114-240 for pigs, 200-500 for chickens, and 400-900 for ducks. Since the dosage of vitamin D is in μg, when fat-soluble vitamin D 2 is mixed with food or feed, it is difficult to control the dosage and it is not easy to mix evenly, resulting in unqualified products. Therefore, the products added with vitamin D 2 in the domestic food or feed industry Very few. The current annual consumption of vitamin D2 in the world is about 1800 tons, of which about 70% are used as feed additives. my country's annual demand is about 100 tons. Now the global vitamin D 2 market is dominated by BASF, Roche, and Nissin Chemical, mainly supplying the European and Japanese markets. These vitamin manufacturing giants sell more than 40% of their global vitamin sales through multidimensional and premixed materials. end customers. According to the novelty search report provided by the Sichuan Provincial Patent Information Center, the search results of Chinese and foreign patent databases show that no technical information on water-soluble vitamin D2 has been found.
发明目的:Purpose of the invention:
本发明的目的是针对脂溶性维生素D2存在的上述问题,采用乳化剂将脂溶性维生素D2(医用级、食品级维生素D2,或用麦角甾醇经照射使9、10位键断裂而得的维生素D2粗品),制成能溶于水的水溶性维生素D2方法:The purpose of the present invention is to solve the above-mentioned problem that fat-soluble vitamin D2 exists, adopts emulsifier to make fat-soluble vitamin D2 (medical grade, food grade vitamin D2 , or use ergosterol to make 9, 10 bond breaking and obtain Vitamin D 2 crude product), make water-soluble vitamin D 2 method that can dissolve in water:
发明内容Contents of the invention
本发明所述水溶性维生素D2的制备方法,按如下步骤进行:The preparation method of water-soluble vitamin D of the present invention carries out as follows:
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将乳化剂溶于乙醇中,再加入维生素D2,其中维生素D2与乳化剂、乙醇的比例为1∶(0.2~0.5)∶2(g∶g∶ml),形成维生素D2的乳化液。Dissolve the emulsifier in ethanol, and then add vitamin D2 , wherein the ratio of vitamin D2 to emulsifier and ethanol is 1: (0.2-0.5): 2 (g:g:ml) to form an emulsion of vitamin D2 .
(2)维生素D2载体制剂的乳化(2) Emulsification of vitamin D2 carrier preparation
将大分子物质或合成生物可降解性大分子物质在水中加热溶解,再加入乳化剂搅伴均匀,其中载体制剂与乳化剂的重量比为1∶(0.01~0.02),得维生素D2载体制剂的乳化液。Heat and dissolve the macromolecular substance or synthetic biodegradable macromolecular substance in water, then add an emulsifier and stir evenly, wherein the weight ratio of the carrier preparation to the emulsifier is 1: (0.01-0.02) to obtain the vitamin D 2 carrier preparation of emulsion.
(3)混合乳化(3) mixed emulsification
将维生素D2载体制剂的乳化液调温到65℃~75℃再加维生素D2的乳化液,充分搅伴均匀,得维生素D2混合乳化液,即液体状的水溶性维生素D2。Adjust the temperature of the emulsified solution of the vitamin D 2 carrier preparation to 65° C. to 75° C., add the emulsified liquid of vitamin D 2 and stir well to obtain a mixed emulsified liquid of vitamin D 2 , that is, liquid water-soluble vitamin D 2 .
本发明所述水溶性维生素D2的制备方法较好的方案是在步骤(1)中加入的维生素D2是用麦角甾醇经照射使9、10位键断裂而得的维生素D2粗品。The preferred scheme of the preparation method of the water-soluble vitamin D2 of the present invention is that the vitamin D2 added in the step (1) is the crude product of vitamin D2 obtained by breaking the 9 and 10 bonds with ergosterol through irradiation.
本发明所述水溶性维生素D2的制备方法更好的方案是在步骤(3)后增加以下步骤:The better scheme of the preparation method of water-soluble vitamin D of the present invention is to increase the following steps after step (3):
(4)干燥(4) dry
将维生素D2混合乳化液放入干燥箱内干燥,得块状或粒状的水溶性维生素D2;Put the vitamin D2 mixed emulsion into a drying box to dry to obtain lumpy or granular water-soluble vitamin D2 ;
(5)将干燥后的块状或粒状的水溶性维生素D2碾磨粉碎成粉状,得到粉状的水溶性维生素D2。(5) Grinding and pulverizing the dried massive or granular water-soluble vitamin D 2 into powder to obtain powdery water-soluble vitamin D 2 .
本发明所述水溶性维生素D2的制备方法,也可以按如下步骤进行:The preparation method of water-soluble vitamin D of the present invention can also be carried out as follows:
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将乳化剂溶于乙醇中,再加入维生素D2,其中维生素D2与乳化剂、乙醇的比例为1∶(8~10)∶(8~10)(g∶g∶ml),形成维生素D2的乳化液。Dissolve the emulsifier in ethanol, and then add vitamin D 2 , wherein the ratio of vitamin D 2 to emulsifier and ethanol is 1: (8-10): (8-10) (g:g:ml) to form vitamin D 2 emulsions.
(2)将维生素D2的乳化液与载体制剂混合搅拌均匀,得维生素D2混合乳化液,即液体状的水溶性维生素D2。(2) Mix and stir the vitamin D 2 emulsion and the carrier preparation evenly to obtain a vitamin D 2 mixed emulsion, that is, liquid water-soluble vitamin D 2 .
上述步骤中使用的乳化剂是含有亲水基团和亲脂基团的表面活性剂,多数是酯类。常用的有甘油脂肪酸脂、蔗糖脂肪酸脂、山梨醇脂肪酸酯、丙二醇脂肪酸酯、聚氧乙烯脂肪酸山梨糖醇酯、聚氧乙烯脂肪酸甘油脂等。也可以使用十二烷基硫酸钠,聚乙烯吡咯烷酮等乳化剂。The emulsifier used in the above steps is a surfactant containing a hydrophilic group and a lipophilic group, most of which are esters. Commonly used are glycerin fatty acid ester, sucrose fatty acid ester, sorbitol fatty acid ester, propylene glycol fatty acid ester, polyoxyethylene fatty acid sorbitol ester, polyoxyethylene fatty acid glyceride, etc. Emulsifiers such as sodium lauryl sulfate and polyvinylpyrrolidone can also be used.
上述步骤中使用的大分子物质是葡萄糖、乳酸钙、葡萄酸钙等,合成生物可降解性大分子物质是脂质体、β-环糊精、琼脂聚糖小珠等。The macromolecular substances used in the above steps are glucose, calcium lactate, calcium gluconate, etc., and the synthetic biodegradable macromolecular substances are liposomes, β-cyclodextrin, agarose beads, etc.
采用本发明所述的方法可以将脂溶性维生素D2制成能以所需任意比例溶于水的水溶性维生素D2,能将它制成液体状、粉状、胶囊或片剂,能满足医药、食品、饲料等领域对维生素D2的应用要求。By adopting the method of the present invention, fat-soluble vitamin D2 can be made into water-soluble vitamin D2 which can be dissolved in water in any required ratio, and can be made into liquid, powder, capsule or tablet, which can satisfy Application requirements for vitamin D2 in medicine, food, feed and other fields.
具体实施例specific embodiment
实施例1:Example 1:
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将20g甘油脂肪酸酯溶解于200ml的乙醇中,再加入100g维生素D2,搅伴后形成维生素D2的乳化液;Dissolve 20g of glycerin fatty acid ester in 200ml of ethanol, then add 100g of vitamin D2 , stir to form an emulsion of vitamin D2 ;
(2)维生素D2载体制剂的乳化(2) Emulsification of vitamin D2 carrier preparation
将1000g葡萄糖加蒸馏水加热溶解再加入1%的蔗糖脂肪酸酯搅伴均匀,得到维生素D2载体制剂的乳化液;Heat 1000g of glucose with distilled water to dissolve, then add 1% sucrose fatty acid ester and stir evenly to obtain an emulsion of vitamin D2 carrier preparation;
(3)混合乳化(3) mixed emulsification
将维生素D2载体制剂的乳化液调温到65℃再加入维生素D2的乳化液,充分搅拌均匀,得维生素D2混合乳化液,即液体状的水溶性维生素D2成品,可直接做为药品,食品或饲料的添加剂使用,它能用水均匀的衡释为所需的任意比例。Adjust the temperature of the emulsified solution of the vitamin D2 carrier preparation to 65°C, then add the emulsified liquid of vitamin D2 , and stir well to obtain a mixed emulsified liquid of vitamin D2 , which is a liquid water-soluble vitamin D2 product, which can be directly used as Used as an additive for medicine, food or feed, it can be uniformly released with water in any desired ratio.
实施例2Example 2
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将50g甘油脂肪酸酯溶解于200ml的乙醇中,再加入100g维生素D2,搅拌后形成维生素D2的乳化液;Dissolve 50g of glycerin fatty acid ester in 200ml of ethanol, then add 100g of vitamin D2 , stir to form an emulsion of vitamin D2 ;
(2)维生素D2载体制剂的乳化(2) Emulsification of vitamin D2 carrier preparation
将2000g葡萄糖加蒸馏水加热溶解浓缩制成含糖量90%以上的葡萄糖浆,再加入2%的蔗糖脂肪酸酯搅伴均匀,得到维生素D2载体制剂的乳化液;Add 2000g of glucose to distilled water, heat, dissolve and concentrate to make glucose syrup with a sugar content of more than 90%, then add 2% sucrose fatty acid ester and stir evenly to obtain an emulsion of vitamin D2 carrier preparation;
(3)混合乳化(3) mixed emulsification
将维生素D2载体制剂的乳化液调温到75℃再加入维生素D2的乳化液,充分搅拌均匀,得维生素D2混合乳化液,即液体状的水溶性维生素D2成品,可直接做为药品,食品或饲料的添加剂使用,它能用水均匀的衡释为所需的任意比例。Adjust the temperature of the emulsion of the vitamin D2 carrier preparation to 75°C, then add the emulsion of vitamin D2 , and stir well to obtain a mixed emulsion of vitamin D2 , that is, a liquid water-soluble vitamin D2 product, which can be directly used as Used as an additive for medicine, food or feed, it can be uniformly released with water in any desired ratio.
实施例3Example 3
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将20g甘油脂肪酸酯溶解于200ml的乙醇中,再加入100g用麦角甾醇经照射使9、10位键断裂而得的维生素D2粗品,搅伴后形成维生素D2的乳化液;Dissolve 20g of glycerol fatty acid ester in 200ml of ethanol, then add 100g of vitamin D2 crude product obtained by irradiating 9 and 10 bonds with ergosterol, and stir to form a vitamin D2 emulsion;
(2)维生素D2载体制剂的乳化(2) Emulsification of vitamin D2 carrier preparation
将1000g葡萄糖加蒸馏水加热溶解再加入1%的蔗糖脂肪酸酯搅伴均匀,得到维生素D2载体制剂的乳化液;Heat 1000g of glucose with distilled water to dissolve, then add 1% sucrose fatty acid ester and stir evenly to obtain an emulsion of vitamin D2 carrier preparation;
(3)混合乳化(3) mixed emulsification
将维生素D2载体制剂的乳化液调温到65℃再加入维生素D2的乳化液,充分搅拌均匀,得维生素D2混合乳化液,即液体状的水溶性维生素D2成品,可直接做为药品,食品或饲料的添加剂使用,它能用水均匀的衡释为所需的任意比例。Adjust the temperature of the emulsified solution of the vitamin D2 carrier preparation to 65°C, then add the emulsified liquid of vitamin D2 , and stir well to obtain a mixed emulsified liquid of vitamin D2 , which is a liquid water-soluble vitamin D2 product, which can be directly used as Used as an additive for medicine, food or feed, it can be uniformly released with water in any desired ratio.
实施例4Example 4
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将50g甘油脂肪酸酯溶解于200ml的乙醇中,再加入100g维生素D2,搅拌后形成维生素D2的乳化液;Dissolve 50g of glycerin fatty acid ester in 200ml of ethanol, then add 100g of vitamin D2 , stir to form an emulsion of vitamin D2 ;
(2)维生素D2载体制剂的乳化(2) Emulsification of vitamin D2 carrier preparation
将2000g葡萄糖加蒸馏水加热溶解浓缩制成含糖量90%以上的葡萄糖浆,再加入2%的蔗糖脂肪酸酯搅伴均匀,得到维生素D2载体制剂的乳化液;Add 2000g of glucose to distilled water, heat, dissolve and concentrate to make glucose syrup with a sugar content of more than 90%, then add 2% sucrose fatty acid ester and stir evenly to obtain an emulsion of vitamin D2 carrier preparation;
(3)混合乳化(3) mixed emulsification
将维生素D2载体制剂的乳化液调温到75℃再加入维生素D2的乳化液,充分搅拌均匀,得维生素D2混合乳化液,即液体状的水溶性维生素D2成品,可直接做为药品,食品或饲料的添加剂使用,它能用水均匀的衡释为所需的任意比例。Adjust the temperature of the emulsion of the vitamin D2 carrier preparation to 75°C, then add the emulsion of vitamin D2 , and stir well to obtain a mixed emulsion of vitamin D2 , that is, a liquid water-soluble vitamin D2 product, which can be directly used as Used as an additive for medicine, food or feed, it can be uniformly released with water in any desired ratio.
(4)干燥(4) dry
将维生素D2混合乳化液放入干燥箱内干燥,得块状或粒状的水溶性维生素D2;Put the vitamin D2 mixed emulsion into a drying box to dry to obtain lumpy or granular water-soluble vitamin D2 ;
(5)将干燥后的块状或粒状的水溶性维生素D2碾磨粉碎成粉状,得到粉状的水溶性维生素D2。(5) Grinding and pulverizing the dried massive or granular water-soluble vitamin D 2 into powder to obtain powdery water-soluble vitamin D 2 .
实施例5Example 5
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将1000g聚乙烯吡咯烷酮加入1000ml乙醇中溶解,再加入50g十二烷基硫酸钠,搅拌混合均匀,然后再加入含100g维生素D2的200ml乙醇溶液,搅拌混合均匀,得维生素D2的乳化液;Add 1000g of polyvinylpyrrolidone to dissolve in 1000ml of ethanol, then add 50g of sodium lauryl sulfate, stir and mix evenly, then add 200ml of ethanol solution containing 100g of vitamin D2 , stir and mix evenly to obtain an emulsion of vitamin D2 ;
(2)混合乳化(2) mixed emulsification
将载体制剂糊精2850g与维生素D2乳化液混合搅拌均匀,得液体状的水溶性维生素D2。Mix 2850 g of carrier preparation dextrin with vitamin D 2 emulsion and stir evenly to obtain liquid water-soluble vitamin D 2 .
实施例6Example 6
(1)维生素D2的乳化(1) Emulsification of Vitamin D 2
将750g聚乙烯吡咯烷酮加入800ml乙醇中溶解,再加入50g十二烷基硫酸钠,搅拌混合均匀,然后再加入含100g维生素D2的200ml乙醇溶液,搅拌混合均匀,得维生素D2的乳化液;Add 750g of polyvinylpyrrolidone to dissolve in 800ml of ethanol, then add 50g of sodium lauryl sulfate, stir and mix evenly, then add 200ml of ethanol solution containing 100g of vitamin D2 , stir and mix evenly to obtain an emulsion of vitamin D2 ;
(2)混合乳化(2) mixed emulsification
将载体制剂糊精4100g与维生素D2乳化液混合搅拌均匀,得液体状的水溶性维生素D2。Mix and stir 4100 g of carrier preparation dextrin and vitamin D 2 emulsion evenly to obtain liquid water-soluble vitamin D 2 .
(3)干燥(3) dry
将维生素D2混合乳化液放入干燥箱内干燥,得块状或粒状的水溶性维生素D2;Put the vitamin D2 mixed emulsion into a drying box to dry to obtain lumpy or granular water-soluble vitamin D2 ;
(4)将干燥后的块状或粒状的水溶性维生素D2碾磨粉碎成粉状,得到粉状的水溶性维生素D2。(4) Grinding and pulverizing the dried massive or granular water-soluble vitamin D 2 into powder to obtain powdery water-soluble vitamin D 2 .
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100409039A CN100364969C (en) | 2004-10-25 | 2004-10-25 | Water soluble vitamins D2 preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100409039A CN100364969C (en) | 2004-10-25 | 2004-10-25 | Water soluble vitamins D2 preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1765882A true CN1765882A (en) | 2006-05-03 |
CN100364969C CN100364969C (en) | 2008-01-30 |
Family
ID=36742024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100409039A Expired - Lifetime CN100364969C (en) | 2004-10-25 | 2004-10-25 | Water soluble vitamins D2 preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100364969C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302168A (en) * | 2011-05-19 | 2012-01-04 | 四川内江汇鑫制药有限公司 | Vitamin D2 oil and preparation method thereof |
CN107156456A (en) * | 2017-05-15 | 2017-09-15 | 南京群汇化工有限公司 | 25 hydroxycholecalciferol inclusion compounds and its preparation method and application |
CN114230499A (en) * | 2021-12-20 | 2022-03-25 | 四川内江汇鑫制药有限公司 | Water-soluble vitamin D2Preparation method of (1) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59122424A (en) * | 1982-12-29 | 1984-07-14 | Riken Vitamin Co Ltd | Vitamin a composition and its preparation |
JPS62281855A (en) * | 1986-05-29 | 1987-12-07 | Daikin Ind Ltd | Clathrate compound containing vitamin, vitamin derivative or hormone |
-
2004
- 2004-10-25 CN CNB2004100409039A patent/CN100364969C/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302168A (en) * | 2011-05-19 | 2012-01-04 | 四川内江汇鑫制药有限公司 | Vitamin D2 oil and preparation method thereof |
CN102302168B (en) * | 2011-05-19 | 2012-09-05 | 四川内江汇鑫制药有限公司 | Vitamin d2 oil and preparation method thereof |
CN107156456A (en) * | 2017-05-15 | 2017-09-15 | 南京群汇化工有限公司 | 25 hydroxycholecalciferol inclusion compounds and its preparation method and application |
CN114230499A (en) * | 2021-12-20 | 2022-03-25 | 四川内江汇鑫制药有限公司 | Water-soluble vitamin D2Preparation method of (1) |
Also Published As
Publication number | Publication date |
---|---|
CN100364969C (en) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6375353B2 (en) | An oral dosage form comprising 25-hydroxyvitamin D3 and a method comprising administering the oral dosage form to a human once a week | |
US6403116B1 (en) | Coenzyme Q10 formulation | |
AU2009214049B2 (en) | Combination of vitamin D and 25-hydroxyvitamin D 3 | |
JP5593550B2 (en) | Use of 25-hydroxyvitamin D3 to affect human muscle physiology | |
EP2240182B1 (en) | Treating hyperglycemia with 25-hydroxyvitamin d3 and vitamin d | |
TW201306752A (en) | Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child | |
US20110052707A1 (en) | Combination of vitamin d and 25-hydroxyvitamin d 3 | |
CN1835752B (en) | Multivitamin syrup for children or young adults | |
WO2016170388A1 (en) | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation | |
EP3060202A1 (en) | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation | |
CN1765882A (en) | Preparation method of water-soluble vitamin D2 | |
KR20070040371A (en) | Use of alpha ketoglutarate and related compounds to lower plasma lipids | |
CN110584120A (en) | Bone health composition | |
CN100335045C (en) | Poultry ascites preventive agent | |
CN110200086A (en) | A kind of fat or oil composition | |
CN1850270A (en) | Ovotransferrin iron supplement agent, and its preparing method and use | |
US20230256060A1 (en) | Undenatured Type II Collagen as a Supplement for Improved Endurance, Lipid Metabolism, and Oxidative Stress | |
WO2021255646A1 (en) | A copper based composition for animal consumption | |
JP2024539038A (en) | Chondroprotective dietary supplement compositions and methods of use thereof | |
EP4412637A1 (en) | Method for treating skeletal articulations and composition and uses thereof | |
CN114230499A (en) | Water-soluble vitamin D2Preparation method of (1) | |
TW201713320A (en) | New use of lycopene and preparation of lycopene based on the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Sichuan Neijiang Huixin Pharmaceutical Co.,Ltd. Assignor: Chen Guoping Contract record no.: 2011510000262 Denomination of invention: Method for preparing water soluble vitamin D[sub]2[/sub] Granted publication date: 20080130 License type: Exclusive License Open date: 20060503 Record date: 20110908 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180807 Address after: 641000 185 Gonghe street, Baima Town, Shizhong District, Neijiang, Sichuan Patentee after: SICHUAN NEIJIANG HUIXIN PHARMACEUTICAL Co.,Ltd. Address before: 641000 188 Forest Farm Road, Baima Town, Neijiang, Sichuan (Sichuan Xing Ming Tai Machinery Co., Ltd.) Patentee before: Chen Guoping |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080130 |